The mitochondrial regulator MNRR1 is reduced in several pathologies, including the mitochondrial heteroplasmic disease MELAS, and genetic restoration of its level normalizes the pathological phenotype. Here, we investigate the upstream mechanism that reduces MNRR1 levels. We have identified the hypoxic regulator HIF2α to bind the MNRR1 promoter and inhibit transcription by competing with RBPJκ. In MELAS cells, there is a pseudohypoxic state that transcriptionally induces HIF2α and stabilizes HIF2α protein. MELAS cybrids harboring the m.3243A > G mutation display reduced levels of prolyl hydroxylase 3 (PHD3), which contributes to the HIF2α stabilization. These results prompted a search for compounds that could increase MNRR1 levels pharmacologically. The screening of a 2400-compound library uncovered the antifungal drug nitazoxanide and its metabolite tizoxanide as enhancers of MNRR1 transcription. We show that treating MELAS cybrids with tizoxanide restores cellular respiration, enhances mitophagy, and, importantly, shifts heteroplasmy toward wild-type mtDNA. Furthermore, in fibroblasts from MELAS patients, the compound improves mitochondrial biogenesis, enhances autophagy, and protects from LPS-induced inflammation. Mechanistically, nitazoxanide reduces HIF2α levels by increasing PHD3. Chemical activation of MNRR1 is thus a potential strategy to improve mitochondrial deficits seen in MELAS. Finally, our data suggests a broader physiological pathway wherein two proteins, induced under severe (1% O2; HIF2α) and moderate (4% O2; MNRR1) hypoxic conditions, regulate each other inversely.
Background: Although chemotherapeutics have proven to be effective in treating metastatic breast cancer, their limited target selectivity has resulted in adverse side effects, rendering them unsuitable for long-term usage. Alternatively, certain natural extracts provide a promising strategy to selectively target cancer while being safe to consume. Specifically, paradise tree (Simarouba glauca) has shown potential anti-tumour activity; however, its efficacy against cancer, mechanism of action, and interaction with standard chemotherapies have not been investigated. Method: We have demonstrated the anti-tumour activity of ethanolic paradise tree extract (PTE) in triple-negative and ER-positive breast cancer cell lines and its interaction with chemotherapeutics when used in combination. The anti-tumour efficacy of PTE was evaluated through the expression of apoptotic biochemical markers as well as changes in cell morphology. For mechanistic studies, fluorogenic dyes were used to quantify reactive oxygen species production and mitochondrial membrane potential destabilization. Results: Our results have shown that PTE selectively triggers apoptosis in breast cancer cells while having limited effects on noncancerous cells. Importantly, we have found that PTE enhances the anti-tumour efficacy of chemotherapeutics, cisplatin and Taxol, when given in combination, while reducing their toxicity in noncancerous cells. Furthermore, PTE inhibits growth of human tumour xenografts in immunocompromised mice. Importantly, PTE in combination with Taxol and cisplatin had the best anti-tumour effect. Conclusion: Our findings suggest that PTE could be a safe and effective treatment for breast cancer. Most importantly, as a supplement to chemotherapeutic regimens, it could enhance anti-tumour effects and reduce chemo-related toxicity